TMCnet News

Bragar Eagel & Squire, P.C. is Investigating Obalon Therapeutics, Inc. (OBLN) on Behalf of Stockholders and Encourages Investors to Contact the Firm
[January 23, 2018]

Bragar Eagel & Squire, P.C. is Investigating Obalon Therapeutics, Inc. (OBLN) on Behalf of Stockholders and Encourages Investors to Contact the Firm


Bragar Eagel & Squire, P.C. is investigating potential claims against Obalon Therapeutics, Inc. (NASDAQ:OBLN). Our investigation concerns whether Obalon has violated the federal securities laws and/or engaged in other unlawful business practices.

On January 23, 2018, Obalon announced the termination of the underwriting agreement and cancellation of its previously announced public stock offering, after, according to the Company, a purported whistleblower contacted KPMG LLP, the Company's independent auditors, to make certain allegations relating to allegedly improper revenue recognition during the Company's fourth fiscal quarter of 2017.

Following this news, the stock price of Obalon fell $1.73 per share, or over 33%, to close at $3.46 per share on January 23, 2017.

If you purchased or otherwise acquired Obalon shares and suffered a loss, continue to hold shares, have information, would like to learn more about these claims, or have an questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.



Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation into Obalon Therapeutics, Inc., please go to http://www.bespc.com/obln. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com.



[ Back To TMCnet.com's Homepage ]